This month, Novartis submitted a letter to the FDA in support of a citizen petition that Pfizer filed in August.
This month, Novartis submitted a letter to the FDA in support of a citizen petition that Pfizer filed in August.
Pfizer’s citizen petition called on the agency to issue guidance clarifying how drug sponsors may communicate about biosimilars, alleging that misinformation communicated to patients, payers, and prescribers, is hindering the growth of the US biosimilar market.
In its comment letter, Novartis explained that it supports the recent efforts from the FDA and HHS to increase the use of biosimilars, specifically, releasing the Biosimilar Action Plan, holding a public hearing in September 2018, and initiating dialogue around key biosimilar topics through the American Patients First blueprint. However, Novartis notes that it believes the FDA and HHS “could do more to incentivize the use of biosimilars while still ensuring access to and development of novel biological products.”
The letter goes on to discuss the importance of accurate information about biosimilars being disseminated to the public, sharing in Pfizer’s concern, and specifically calling on the FDA and HHS to address multiple “misinformation campaigns” that it believes are hurting biosimilar uptake.
Novartis states that the following misinformation campaigns do not provide balanced information about biosimilar products “but rather infer potential risks and aim at casting doubts about their safety or efficacy”:
The letter also cited results seen in a recent report from FirstWord Pharma that found that 33% of respondents said they had heard negative feedback about biosimilars. “There appears to be a particular strategy among some originator companies to openly question the quality of biosimilars, in addition to negative discussion about their efficacy and safety,” concluded the report.
In order to address these issues, Novartis agreed with Pfizer on the need for additional FDA action and oversight “to help ensure a truthful environment exists within which healthcare providers and patients can make treatment decisions without harmful misinformation about biosimilars.”
Specifically, Novartis recommends that the FDA take the following actions: partner with the Federal Trade Commissioner to identify and address these campaigns, issue correspondence directing these organizations to stop publishing misinformation campaigns, establish a public list of which companies or organizations are conducting such campaigns, and enhance educational outreach efforts to contest the campaigns.
Finally, Novartis encouraged the FDA to publish a “Facts About Biosimilars” page on its website to address the most common misinformation and misunderstood elements about biosimilars. In order to deliver the content to a broader audience, Novartis suggested that the FDA work with and leverage relationships with healthcare provider organizations as well as patient advocacy organizations to ensure their members have access to it.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.